BioCentury
ARTICLE | Clinical News

Genasense oblimersen sodium injection): Preliminary Phase II data

December 7, 2009 8:00 AM UTC

Preliminary data from an ongoing, open-label, U.S. Phase II trial in 10 patients with stage IV metastatic melanoma showed that 900 mg IV Genasense twice weekly for 4 weeks plus Temodar temozolomide a...